Other
The Biostatistics and Therapy Evaluation Unit
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 4 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
1(100.0%)
1Total
N/A(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT02536625Completed
Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
Role: collaborator
NCT01306188Completed
Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer Patients
Role: collaborator
NCT02024035Completed
Protocole Advanced RadioTherapy ORL
Role: collaborator
NCT00870116Not ApplicableUnknown
Stereotactic Body Radio Therapy (SBRT) for Early-stage Non Small Cell Lung Cancer (NSCLC)
Role: collaborator
All 4 trials loaded